F. Hoffmann-La Roche had nine patents in big data during Q4 2023. The patents filed by F. Hoffmann-La Roche Ltd in Q4 2023 include methods for screening subjects for chronic kidney disease risk, processing data from analytical instruments, analyzing clinical trial data retrospectively, alerting users about blood glucose levels, and determining the risk of mortality for cancer patients using a mathematical model. GlobalData’s report on F. Hoffmann-La Roche gives a 360-degreee view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights F. Hoffmann-La Roche Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

F. Hoffmann-La Roche grant share with big data as a theme is 0% in Q4 2023. Grant share is based on the ratio of number of grants to total number of patents.

Recent Patents

Application: Method for screening a subject for the risk of chronic kidney disease (Patent ID: US20230417772A1)

The patent filed by F. Hoffmann-La Roche Ltd. describes a method for screening a subject for the risk of chronic kidney disease (CKD) by receiving marker data related to various parameters such as age, time since diabetes diagnosis, creatinine levels, estimated glomerular filtration rate, albumin levels, and blood urea nitrogen levels. A risk factor is then determined based on these parameters to indicate the likelihood of the subject suffering from CKD. The method involves utilizing a machine learning model, specifically an XGBoost model, to analyze the data and determine the risk factor accurately.

Furthermore, the patent outlines a computer-implemented method for screening subjects for CKD using a data processing system with a processor and memory. The method involves receiving marker data, determining a risk factor using a machine learning model, and training the model based on a set of training data that includes parameters like age, creatinine levels, albumin levels, and blood urea nitrogen levels. The risk factor is determined without any imputed marker data, ensuring the accuracy of the screening process. Additionally, the patent covers a system comprising a processor and memory to perform the screening method, as well as a non-transitory computer-readable medium storing instructions for executing the method.

To know more about GlobalData’s detailed insights on F. Hoffmann-La Roche, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.